argenx SE
ARGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $64.2B
$1,033.15
▼ -1.93%
P/E
76.59
Mkt Cap
$64.2B
52-Wk Range
$661.85–$1,073
52-Week Range
$661.85 - $1,072.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.0).
- Significant premium - growth priced in
Growth
Strong growth ahead
Value
Significant premium - growth priced in
Momentum
Strong
+15.9% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ARGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 22, 2026
JUL 23, 2026
Reported EPS of $7.32 vs $6.27 consensus (+16.8% surprise). Revenue of $2.8B vs $1.9B expected (+51.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.8%
Revenue trend · last 1Q
+197%
Q2 26
$2.8B
Margins · last 1Q
Gross
90.1%
Operating
30.1%
Profit
29.8%
Wall Street consensus
13 analysts · 92% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
92%
Hold
8%
Sell
0%
Median Price Target
—
Latest: UBS · Aug 26, 2026
vs Industry
How ARGX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.